Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect
BioMarin has followed through on its shift to external innovation, inking a deal to add a phase 3 enzyme replacement therapy to its pipeline.
Nick Paul Taylor
May 16, 2025 8:46am
Lilly strengthens RNA pipeline with $1.3B hearing loss pact
May 16, 2025 7:34am
AbbVie tosses ADARx $335M for siRNA options deal
May 14, 2025 9:00am
Activist investor fails to derail Alumis' Acelyrin merger
May 14, 2025 7:45am
Novo inks $2.2B deal for Septerna's preclinical obesity programs
May 14, 2025 7:00am
GSK pays $1.2B upfront for Boston's lead liver disease drug
May 14, 2025 2:53am
